Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MLNR | O43193 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547510 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL3229383 | 1.00 | CYP2D6 (0.34) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL22260036 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL797872 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL24922624 | 0.97 | CYP2D6 (0.33) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| SCHEMBL1704716 | 0.92 | — | — | |
| SCHEMBL1705094 | 0.92 | — | — | |
| SCHEMBL164043 | 0.92 | — | — | |
| Methane SCHEMBL28330275 | 0.90 | KDM4E (0.38) | CYP2D6CYP1A2KDM4ENPC1HPGD | |
| Hydrochloric Acid SCHEMBL5241681 | 0.90 | KDM4E (0.42) | CYP2D6CYP1A2KDM4ENPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2022-03-10 | — | — | US | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| US-20180044305-A1 | 3-SUBSTITUTED 1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| US-20180044305-A1 | 3-SUBSTITUTED 1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-9657022-B2 | 7-OXO-1,6-diazabicyclo[3.2.1]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-05-23 | — | — | US | disclosed |
| US-9657022-B2 | 7-OXO-1,6-diazabicyclo[3.2.1]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-05-23 | — | — | US | disclosed |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2017-02-16 | — | — | US | disclosed |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2017-02-16 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | CYP2D6 1125/4885CYP1A2 1183/4885KDM4E 4195/4885 |
| US-20180044305-A1 | 3-SUBSTITUTED 1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 1198/4885CYP1A2 689/4885KDM4E 2493/4885 |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | CYP2D6 5/4885CYP1A2 1/4885KDM4E 2381/4885 |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | CYP2D6 888/4885CYP1A2 4059/4885KDM4E 2103/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | CYP2D6 4691/4885CYP1A2 4596/4885KDM4E 486/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CYP2D6 361/4885CYP1A2 110/4885KDM4E 2583/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | CYP2D6 2989/4885CYP1A2 2991/4885KDM4E 1975/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP2D6 3211/4885CYP1A2 2070/4885KDM4E 791/4885 |
| US-20170044159-A1 | 7-OXO-1,6-DIAZABICYCLO[3.2.1 ]OCTANE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CASP7, ODC1, CASP1 | CYP2D6 43/4885CYP1A2 241/4885KDM4E 4179/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CYP2D6 1097/4885CYP1A2 1500/4885KDM4E 1388/4885 |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | CYP2D6 4/4885CYP1A2 1/4885KDM4E 2151/4885 |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | HAO2, AHR, HMOX1 | CYP2D6 101/4885CYP1A2 35/4885KDM4E 3404/4885 |
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 1187/4885CYP1A2 503/4885KDM4E 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.